More than 50% of all melanomas harbor activating BRAF kinase mutations, with BRAFV600E representing more than 90% of BRAF mutations3,4, the consequence of which is the constitutive activation of RAF-mitogen activated protein kinase (MAPK) and extracellular signal-regulated kinase (ERK) signaling to promote melanoma proliferation and resistance to apoptosis5. Here, WNK2 is linked to melanoma.